The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants.
The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.
The 4,094 residents of Shanghai communities who have been enrolled in the STONE cohort.
Individuals who completed the baseline questionnaire survey, physical examination, and related clinical tests between 2016 and 2017, with complete data records.
Willingness to participate in this follow-up study and provision of informed consent.
Participants who have moved away from their original community and have been living elsewhere for more than two years.
Participants whose contact information has changed or become invalid, resulting in loss of contact (those who remain uncontactable after three attempts to reach out).
A total of 4,094 residents were drawn from 10 communities in Shanghai, with baseline multidimensional data collected."
Cohort
Prospective
Not listed
Number of Participants Who developed cardiovascular diseases.
The diagnosis of cardiovascular diseases should be made according to the outcomes of carotid ultrasound and cardiac biomarkers.
Number of Participants Who developed metabolic disorders.
Metabolic disorders include obesity, dyslipidemia, diabetes, fatty liver diseases, hypertension, hyperuricemia, chronic kidney disease, thyroid diseases, and bone metabolism-related disorders.
Click on the lead sponsor to view all of their trials.
